Clinical update on immunotherapy for breast cancer provided by BriaCell

An immune-oncology focused biotechnology company, BriaCell, has provided a clinical update on its lead immunotherapy drug for advanced breast cancer.

The company is currently enrolling patients in two separate but related clinical trials designed to evaluate Bria-IMT (formerly referred to as SV-BR-1-GM) in metastatic or locally recurrent breast cancer patients as well as in combination with Keytruda or Yervoy.

Patient recruitment is on schedule despite interruption due to temporary shutdown of some clinical sites, affected by wildfires and hurricanes.

Based on results to-date, Bria-IMT has been very well tolerated and the majority of adverse events were limited to expected minor local irritation at the injection sites. No serious adverse events related to Bria-IMT have been reported and no new or unexpected safety issues related to the therapy have been observed.